Md Nesran Zarith Nameyrra, Shafie Nurul Husna, Md Tohid Siti Farah, Norhaizan Mohd Esa, Ismail Amin
Department of Nutrition and Dietetics, Universiti Putra Malaysia, 43400 Serdang, Malaysia.
Laboratory of UPM-MAKNA Cancer Research, Institute of Bioscience UPM, 43400 Serdang, Malaysia.
Evid Based Complement Alternat Med. 2020 Mar 21;2020:7958041. doi: 10.1155/2020/7958041. eCollection 2020.
In many studies, green tea epigallocatechin-3-gallate (EGCG) has already shown its therapeutic effects in colorectal cancer cells (CRC). However, its mechanism of actions in CRC is poorly elucidated. Hence, this study attempts to elucidate the mechanism of actions of green tea ECGG via iron chelation activity in CRC. In order to investigate this property, HT-29 cell lines (CRC) were treated with EGCG for 24 h, 48 h, and 72 h. From western blot analysis, EGCG had upregulated transferrin receptor (TfR) protein and downregulated Ferritin-H (FtH) protein indicating that iron chelation activity has occurred in CRC. Meanwhile, the molecular docking study demonstrated that EGCG is able to strongly interact the ferritin protein with a high binding affinity (-7.3 kcal/mol) via strong hydrogen bindings to glutamic acid 64 and lysine 71; two moderate hydrogen bindings to asparagine 74 and a hydrophobic interaction to the hydrophobic pocket of lysine 71. The strong interaction predicted between EGCG to ferritin may lead to inhibition of ferritin by EGCG, thus supporting the downregulation of FtH observed in in vitro studies. Molecular docking study of TfR to EGCG cannot be modulated based on the in vitro results. In conclusion, EGCG possesses iron chelator property in CRC and this potential could be further exploited for CRC treatment.
在许多研究中,绿茶表没食子儿茶素-3-没食子酸酯(EGCG)已在结肠癌细胞(CRC)中显示出其治疗效果。然而,其在CRC中的作用机制尚不清楚。因此,本研究试图通过CRC中的铁螯合活性来阐明绿茶EGCG的作用机制。为了研究这一特性,用EGCG处理HT-29细胞系(CRC)24小时、48小时和72小时。从蛋白质印迹分析来看,EGCG上调了转铁蛋白受体(TfR)蛋白,下调了铁蛋白-H(FtH)蛋白,表明CRC中发生了铁螯合活性。同时,分子对接研究表明,EGCG能够通过与谷氨酸64和赖氨酸71形成强氢键、与天冬酰胺74形成两个中等强度氢键以及与赖氨酸71的疏水口袋形成疏水相互作用,以高结合亲和力(-7.3千卡/摩尔)与铁蛋白强烈相互作用。EGCG与铁蛋白之间预测的强相互作用可能导致EGCG对铁蛋白的抑制,从而支持体外研究中观察到的FtH下调。基于体外结果,无法调节TfR与EGCG的分子对接研究。总之,EGCG在CRC中具有铁螯合剂特性,这一潜力可进一步用于CRC治疗。